Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Patient-reported outcomes from IMvigor011: A phase 3 study of circulating tumor (ct)DNA-guided adjuvant atezolizumab vs placebo in muscle-invasive bladder cancer (MIBC).

Time to confirmed deterioration in physical functioning, role functioning, and global health status/quality of life showed no evidence of a difference between atezolizumab and placebo. More than 90% of patients in both arms reported little or no treatment side-effect burden through cycle 11. The abstract concludes ctDNA-guided adjuvant atezolizumab improved DFS and OS without negatively affecting patient-reported quality of life.

ASCO Annual Meeting 2026PubMed 41124204